Newbury Pharmaceuticals AB Cash Flow Conversion Efficiency
Newbury Pharmaceuticals AB cash flow conversion efficiency. Based on the latest financial reports, Newbury Pharmaceuticals AB (NEWBRY) has a cash flow conversion efficiency ratio of 0.072x as of February 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr2.26 Million ≈ $243.21K USD) by net assets (Skr31.30 Million ≈ $3.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Newbury Pharmaceuticals AB (2021–2024)
Cash flow conversion efficiency of Newbury Pharmaceuticals AB from 2021 to 2024. This chart illustrates how Newbury Pharmaceuticals AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Newbury Pharmaceuticals AB stock quote for real-time trading data and today's change.
Newbury Pharmaceuticals AB Cash Flow Conversion Ratio Explained
Newbury Pharmaceuticals AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Newbury Pharmaceuticals AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Newbury Pharmaceuticals AB ranked by their cash flow conversion efficiency. Also see NEWBRY company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Celtic plc
LSE:CCPC
|
-0.038x |
|
abrdn Asian Income Fund Limited
LSE:AAIF
|
0.031x |
|
Australasian Metals Ltd
AU:A8G
|
-0.053x |
|
ESE Entertainment Inc
V:ESE
|
-0.052x |
|
Idealist Gayrimenkul Yatirim Ortakligi AS
IS:IDGYO
|
-0.393x |
|
Woodlandor Holdings Bhd
KLSE:7025
|
-0.017x |
|
Sundaram Multi Pap Limited
NSE:SUNDARAM
|
-0.097x |
|
Datametrex AI Ltd
V:DM
|
-0.189x |
Annual Cash Flow Conversion Efficiency for Newbury Pharmaceuticals AB (2021–2024)
The table below shows the annual cash flow conversion efficiency of Newbury Pharmaceuticals AB from 2021 to 2024. Review Newbury Pharmaceuticals AB free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-08-31 | Skr51.92 Million ≈ $5.59 Million |
Skr-23.71 Million ≈ $-2.55 Million |
-0.457x | +2.92% |
| 2023-08-31 | Skr49.38 Million ≈ $5.31 Million |
Skr-23.23 Million ≈ $-2.50 Million |
-0.470x | -115.64% |
| 2022-08-31 | Skr68.77 Million ≈ $7.40 Million |
Skr-15.00 Million ≈ $-1.61 Million |
-0.218x | -106.38% |
| 2021-08-31 | Skr38.47 Million ≈ $4.14 Million |
Skr-4.07 Million ≈ $-437.57K |
-0.106x | -- |
About Newbury Pharmaceuticals AB
Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.